![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bellicum Pharmaceuticals Inc (PK) | USOTC:BLCM | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.07475 | 0.0731 | 0.0897 | 0.00 | 01:00:00 |
|
|
|
Delaware
|
|
20-1450200
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
2130 W. Holcombe Blvd., Ste. 800
Houston, Texas
|
|
77030
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Karen E. Deschaine, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
Tel: (858) 550-6000
|
Atabak Mokari
Chief Financial Officer
Bellicum Pharmaceuticals, Inc.
2130 W. Holcombe Blvd., Ste. 800
Houston, Texas 77030
(832) 384-1100
|
|
|
|
|
|
|
|
|
Large Accelerated filer
|
|
¨
|
|
|
Accelerated filer
|
|
x
|
|
|
|
|
|
|
||
Non-accelerated filer
|
|
¨
|
|
|
Smaller reporting company
|
|
x
|
|
|
|
|
|
Emerging growth company
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Title of securities
to be registered
|
|
Amount
to be
registered (1)
|
|
Proposed
maximum
offering price
per share (3)
|
|
Proposed
maximum
aggregate
offering price (3)
|
|
Amount of
registration fee
|
|
2019 Equity Incentive Plan
Common Stock, $0.01 par value per share
|
|
6,000,000 shares (2)
|
|
$1.49
|
|
$8,940,000
|
|
$1,160.41
|
|
|
|||||||||
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock (“Common Stock”) that become issuable under the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended (the “2019 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction.
|
(2)
|
Represents an increase in the number of shares of Common Stock reserved for issuance under the 2019 Plan pursuant to an amendment to the 2019 Plan approved by the Registrant’s stockholders at the Registrant’s Special Meeting of Stockholders held on January 15, 2020.
|
(3)
|
This estimate is made pursuant to Rule 457(h) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The maximum offering price per share and the maximum aggregate offering price are calculated on the basis of the average of the high and low sales prices of the Registrant’s Common Stock on January 28, 2020, as reported on the Nasdaq Global Market.
|
(1)
|
Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on December 23, 2014, and incorporated herein by reference.
|
(2)
|
Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
|
(3)
|
Previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on December 23, 2014, and incorporated herein by reference.
|
(4)
|
Previously filed as Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-200328), originally filed with the Commission on November 18, 2014, as amended, and incorporated herein by reference.
|
(5)
|
Previously filed as Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-200328), originally filed with the Commission on November 18, 2014, as amended, and incorporated herein by reference.
|
(6)
|
Previously filed as Exhibit 4.3 to the Registrant’s Registration Statement on Form S-3(File No. 333-209012), originally filed with the Commission on January 15, 2016, and incorporated herein by reference.
|
(7)
|
Previously filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
|
(8)
|
Previously filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
|
(9)
|
Previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
|
*
|
Filed herewith.
|
|
|
|
Bellicum Pharmaceuticals, Inc.
|
||
|
|
|
By:
|
|
/s/ Richard A. Fair
|
|
|
Richard A. Fair
|
|
|
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
|
/s/ Richard A. Fair
|
President, Chief Executive Officer and Director
|
January 29, 2020
|
|
Richard A. Fair
|
(Principal Executive Officer)
|
|
|
/s/ Atabak Mokari
|
Chief Financial Officer
|
January 29, 2020
|
|
Atabak Mokari
|
(Principal Financial Officer)
|
|
|
/s/ David E. Strauss
|
Corporate Controller
|
January 29, 2020
|
|
David E. Strauss
|
(Principal Accounting Officer)
|
|
|
/s/ James Brown
|
Director (Chairman)
|
January 29, 2020
|
|
James Brown
|
|
|
|
/s/ James M. Daly
|
Director
|
January 29, 2020
|
|
James M. Daly
|
|
|
|
|
Director
|
January 29, 2020
|
|
Stephen R. Davis
|
|
|
|
/s/ Reid M. Huber, Ph.D.
|
Director
|
January 29, 2020
|
|
Reid M. Huber, Ph.D.
|
|
|
|
/s/ Judith V. Klimovsky, M.D.
|
Director
|
January 29, 2020
|
|
Judith V. Klimovsky, M.D.
|
|
|
|
/s/ Jon P. Stonehouse
|
Director
|
January 29, 2020
|
|
Jon P. Stonehouse
|
|
|
|
1 Year Bellicum Pharmaceuticals (PK) Chart |
1 Month Bellicum Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions